CN104623415A - Pharmaceutical composition for treating nephropathy and application thereof - Google Patents
Pharmaceutical composition for treating nephropathy and application thereof Download PDFInfo
- Publication number
- CN104623415A CN104623415A CN201510067309.7A CN201510067309A CN104623415A CN 104623415 A CN104623415 A CN 104623415A CN 201510067309 A CN201510067309 A CN 201510067309A CN 104623415 A CN104623415 A CN 104623415A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- radix
- semen
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicine and particularly relates to a pharmaceutical composition for treating nephropathy and application thereof. The pharmaceutical composition comprises the following components: astragalus membranaceus, tuckahoe, fructus lycii, corn stigma, radix achyranthis bidentatae, bighead atractylodes rhizome, codonopsis pilosula, cortex acanthopanacis, ginger processed pinellia, honeysuckle, herba lycopi, semen coicis, red peony root, semen lepidii, ricepaper pith and madder. The pharmaceutical composition provided by the invention is a pure pharmaceutical composition, the prescription is reasonable, differentiation administration is carried out, and the pharmaceutical composition has a good curative effect on nephropathy, particularly spleen deficiency and dampness type primary nephropathy.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of medical composition and its use for the treatment of nephropathy.
Background technology
Nephrotic syndrome (nephroticsyndrome, NS) refers to one group of clinical syndrome, shows as a large amount of albuminuria, hypoproteinemia, hyperlipemia and edema in various degree.The cause of disease of nephrotic syndrome is divided into constitutional and the large class of Secondary cases two.Primary nephrotic syndrome belongs to Chinese medicine " edema " category, and edema caused by it mostly is diseases caused by exogenous pathogenic factor water and wets, and spleen sun is stranded, or improper diet and overtiredness etc. undermines temper, or natural endowment is not enough, prolonged illness overstrain undermines kidney qi, causes spleen to lose and transfers, kidney mistake is opened entire, and retention of water-damp in the body, is into edema.Treatment by Chinese herbs NS curative effect is reliable, with the obvious advantage, especially alleviating hormone side effect, smoothly corticosterone reduction, improve in the integral status of patient etc. and have incomparable advantage compared with western medical treatment, dialectical, differential diagnosis of diseases, correctly, reasonably use Chinese medicine, can clinical efficacy be improved to a certain extent, be conducive to clinical application.
Summary of the invention
The invention provides a kind of new pharmaceutical composition for the treatment of nephropathy, overcome prior art deficiency, have good curative effect, and toxic and side effects is little.Described pharmaceutical composition is obtained by following raw material: the Radix Astragali, Poria, Fructus Lycii, Stigma Maydis, Radix Achyranthis Bidentatae, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Cortex Acanthopancis, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Flos Lonicerae, Herba Lycopi, Semen Coicis, Radix Paeoniae Rubra, Semen Lepidii (Semen Descurainiae).
Preferably, described pharmaceutical composition also comprises Medulla Tetrapanacis and Radix Rubiae.
The technical scheme adopted for solving its technical problem is the pharmaceutical composition of described treatment nephropathy, is made up of the medicine of following weight: Radix Astragali 18-20 part, Poria 16-18 part, Fructus Lycii 15-17 part, Stigma Maydis 13-15 part, Radix Achyranthis Bidentatae 10-12 part, Rhizoma Atractylodis Macrocephalae 12-15 part, Radix Codonopsis 8-10 part, Cortex Acanthopancis 8-10 part, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 5-9 part, Flos Lonicerae 4-6 part, Herba Lycopi 5-7 part, Semen Coicis 8-10 part, Radix Paeoniae Rubra 7-9 part, Semen Lepidii (Semen Descurainiae) 4-6 part.
Preferably, described pharmaceutical composition also comprises the medicine of following weight: Medulla Tetrapanacis 10-12 part and Radix Rubiae 6-8 part.
Most preferred technique scheme of the present invention is, described pharmaceutical composition of the present invention, is obtained by the raw material of following weight portion: the Radix Astragali 19 parts, 17 parts, Poria, Fructus Lycii 16 parts, Stigma Maydis 14 parts, Radix Achyranthis Bidentatae 11 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, Radix Codonopsis 9 parts, Cortex Acanthopancis 9 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 7 parts, Flos Lonicerae 5 parts, Herba Lycopi 6 parts, Semen Coicis 9 parts, Radix Paeoniae Rubra 8 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Medulla Tetrapanacis 11 parts, 7 parts, Radix Rubiae.
Present invention also offers the preparation method of described pharmaceutical composition, specifically comprise the steps: the raw material Radix Astragali of above-mentioned weight portion, Poria, Fructus Lycii, Stigma Maydis, Radix Achyranthis Bidentatae, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Cortex Acanthopancis, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Flos Lonicerae, Herba Lycopi, Semen Coicis, Radix Paeoniae Rubra, Semen Lepidii (Semen Descurainiae), after Medulla Tetrapanacis and Radix Rubiae are pulverized respectively, after warm water lixiviate 2h, filter to obtain lixiviating solution, add equivalent soak by water 2 times, each 1.5 hours, filter, being concentrated into relative density after lixiviating solution and filtrate merge is 1.10-1.12 (surveying for 80 DEG C), room temperature to be chilled to, adding ethanol makes alcohol content reach 75%, leave standstill 24 hours, leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10-1.12 (80 DEG C of surveys), namely Chinese medical concrete is obtained after drying.
Those skilled in the art directly can be used as medicine on obtained active constituents of medicine basis of the present invention to use or add on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.Preferably, pharmaceutical composition of the present invention conveniently preparation technology be prepared into tablet or capsule.Described capsule is after being pulverized by active component and adjuvant sodium alginate, MgCO
3, stearic acid crosses 80 mesh sieves, mix homogeneously, granulate with dry granulating machine, 20 mesh sieves carry out granulate, particles filledly in hard capsules, namely obtain this product by obtained.
The present invention also asks to protect the purposes of aforementioned pharmaceutical compositions in preparation treatment nephropathy especially Primary Nephrosis medicine, the purposes more especially in preparation treatment stagnation of dampness due to deficiency of the spleen type Primary Nephrosis medicine.In clinical observation process, come off 6 routine cases, and wherein 3 routine patients take a turn for the better backed off after random, and effectively to add up curative effect, the invalid backed off after random of 3 routine patient, with invalid statistics curative effect, all the other all complete clinical observation.Efficacy result is as follows: clinic control 16 example (22.9%), effective 34 examples (48.6%), effective 16 examples (22.9%), invalid 4 examples (5.71%), total effective rate 94.3%.In therapeutic process, vital sign patient steadily and without serious adverse reactions such as allergy, show that the clinical application of we is safely and effectively, is worth studying and applying further.Simultaneously through the albuminous comparison for the treatment of Plasma Before And After, after can drawing treatment, plasma albumin comparatively treats front comparing difference remarkable statistical significance (P < 0.01), and drug regimen of the present invention is described, and I am with the obvious advantage in raising plasma albumin.
Further, pharmaceutical composition of the present invention, the described Radix Astragali, sweet, temperature.Return lung, spleen channel.Invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.
Poria is sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, spleen invigorating mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia.
Fructus Lycii, sweet, flat.Return liver, kidney channel.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.For asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, and blurred vision is failed to understand.
Stigma Maydis is sweet, light, flat.Return bladder, liver, gallbladder meridian.Inducing diuresis to remove edema, suppressing the hyperactive liver function of gallbladder promoting.For acute and chronic nephritis, edema, acute hepatitis, chronic hepatitis, hypertension, diabetes, chronic sinusitis, lithangiuria, Biliary Calculi, the disease such as dysuria, damp and hot jaundice.And can habitual abortion be prevented.
Radix Achyranthis Bidentatae is bitter, sour, flat.Return liver, kidney channel.Invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.For soreness of waist and knee joint, muscles and bones is unable, amenorrhea and mass in the abdomen, dizziness due to hyperactivity of liver-YANG.
The Rhizoma Atractylodis Macrocephalae, bitter, sweet, temperature.Return spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.Rhizoma Atractylodis Macrocephalae spleen invigorating, stomach function regulating, antiabortive.For insufficiency of the spleen lack of appetite, loose stool of having loose bowels, frequent fetal movement.
Radix Codonopsis, sweet, flat.Return spleen, lung meridian.Invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Cortex Acanthopancis, pungent, bitter, temperature.Return liver, kidney channel.Wind-damp dispelling, invigorating the liver and kidney, bone and muscle strengthening.For rheumatic arthralgia, muscles and bones flaccidity is soft, children's's walking retardation in children, and body void is weak, edema, beriberi.
The Rhizoma Pinelliae, pungent, temperature; Poisonous.Return spleen, stomach, lung meridian.Drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.For abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, dizziness due to wind-phlegm, syncope due to accumulation of phlegm is had a headache, vomiting regurgitation, and breast gastral cavity painful abdominal mass is vexed, globus hystericus; Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) is used for stopping nausea and vomiting by lowering the adverse flow of QI.
Flos Lonicerae, sweet, cold.Return lung, the heart, stomach warp.Heat-clearing and toxic substances removing, wind-heat dissipating.For carbuncle furuncle, sore throat, erysipelas, toxic-heat and blood stasis, anemopyretic cold, epidemic febrile disease is generated heat.
Herba Lycopi, bitter, pungent, tepor.Return liver, spleen channel.Blood circulation promoting and blood stasis dispelling, line water detumescence.For menoxenia, amenorrhea, dysmenorrhea, postnatal blood stasis is suffered from abdominal pain, edema.
Semen Coicis is sweet, light, cool.Return spleen, stomach, lung meridian.Spleen invigorating eliminating dampness by diuresis, eliminating impediment antidiarrheal, row is dense in heat clearing away.For edema, beriberi, dysuria, arthralgia chiefly caused by damp pathogen contracture, diarrhea due to hypofunction of the spleen, lung abscess, intestinal carbuncle; Verruca plana.
Radix Paeoniae Rubra, bitter, be slightly cold.Return Liver Channel.Clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, hematemesis and epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea ， mass in the abdomen is suffered from abdominal pain, injury from falling down, carbuncle skin infection.
Semen Lepidii (Semen Descurainiae), pungent, bitter, Great Cold.Return lung, urinary bladder channel.Eliminating pathogen from the lung for relieving asthma, line water detumescence.Stop up lung for sputum, dyspnea and cough with excessive sputum, fullness and distention in the chest and hypochondrium, must not put down sleeping, and ascites pleural fluid swells, dysuria; Pulmonary heart disease edema.
Medulla Tetrapanacis, sweet, light, be slightly cold.Attach to the lung and stomach meridians.Clearing away heat and promoting diuresis, ventilation stimulating milk secretion.For hygropyrexia dark coloured urine, the puckery pain of gonorrhea, edema oliguria, agalactia.
Radix Rubiae, bitter, cold.Return Liver Channel.Removing heat from blood, hemostasis, blood stasis dispelling, stimulates the menstrual flow.For spitting blood, epistaxis, metrorrhagia, traumatic hemorrhage, amenorrhea stasis blocking, arthralgia, tumbling and swelling.
Above-mentioned all medicines share, and mend wherein gas, and help its strong fortune, inducing diuresis to remove edema, the effect of heat clearing away spleen invigorating, especially has clear improvement to stagnation of dampness due to deficiency of the spleen type Primary Nephrosis to Primary Nephrosis.Through clinical practice checking, its determined curative effect, mild in medicine property and, do not occur toxic and side effects and untoward reaction, safety coefficient is high, clinical observation total effective rate nearly 95%.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1
The each raw material of the present invention is taken: the Radix Astragali 19 parts, 17 parts, Poria, Fructus Lycii 16 parts by following weight portion, Stigma Maydis 14 parts, Radix Achyranthis Bidentatae 11 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, Radix Codonopsis 9 parts, Cortex Acanthopancis 9 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 7 parts, Flos Lonicerae 5 parts, Herba Lycopi 6 parts, Semen Coicis 9 parts, Radix Paeoniae Rubra 8 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Medulla Tetrapanacis 11 parts, 7 parts, Radix Rubiae.
Preparation technology is as follows:
By the raw material Radix Astragali of above-mentioned weight portion, Poria, Fructus Lycii, Stigma Maydis, Radix Achyranthis Bidentatae, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Cortex Acanthopancis, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Flos Lonicerae, Herba Lycopi, Semen Coicis, Radix Paeoniae Rubra, Semen Lepidii (Semen Descurainiae), after Medulla Tetrapanacis and Radix Rubiae are pulverized respectively, after warm water lixiviate 2h, filter to obtain lixiviating solution, add equivalent soak by water 2 times, each 1.5 hours, filter, being concentrated into relative density after lixiviating solution and filtrate merge is 1.10-1.12 (surveying for 80 DEG C), room temperature to be chilled to, adding ethanol makes alcohol content reach 75%, leave standstill 24 hours, leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10-1.12 (80 DEG C of surveys), namely Chinese medical concrete is obtained after drying.Those skilled in the art directly can be used as medicine and be used or add adjuvant sodium alginate, MgCO on this basis
3, stearic acid crosses 80 mesh sieves, mix homogeneously, granulate with dry granulating machine, 20 mesh sieves carry out granulate, by obtained particles filled obtained Traditional Chinese medicine preparation capsule agent of the present invention in hard capsules.
When using medicine composite for curing kidney disorders of the present invention, take prepared capsule, containing crude drug amount 0.4g, every day 3 times, each 3, take half an hour after meal for every.
Embodiment 2
The each raw material of the present invention is taken: the Radix Astragali 18 parts, 16 parts, Poria, Fructus Lycii 15 parts by following weight portion, Stigma Maydis 13 parts, Radix Achyranthis Bidentatae 10 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Radix Codonopsis 8 parts, Cortex Acanthopancis 8 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 5 parts, Flos Lonicerae 4 parts, Herba Lycopi 5 parts, Semen Coicis 8 parts, Radix Paeoniae Rubra 7 parts, Semen Lepidii (Semen Descurainiae) 4 parts, Medulla Tetrapanacis 10 parts and 6 parts, Radix Rubiae.
Preparation technology is with embodiment 1.
Embodiment 3
The each raw material of the present invention is taken: the Radix Astragali 20 parts, 18 parts, Poria, Fructus Lycii 17 parts by following weight portion, Stigma Maydis 15 parts, Radix Achyranthis Bidentatae 12 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Codonopsis 10 parts, Cortex Acanthopancis 10 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 9 parts, Flos Lonicerae 6 parts, Herba Lycopi 7 parts, Semen Coicis 10 parts, Radix Paeoniae Rubra 9 parts, Semen Lepidii (Semen Descurainiae) 6 parts, Medulla Tetrapanacis 12 parts and 8 parts, Radix Rubiae.
Preparation technology is with embodiment 1.
Embodiment 4
The each raw material of the present invention is taken: the Radix Astragali 18 parts, 18 parts, Poria, Fructus Lycii 15 parts by following weight portion, Stigma Maydis 15 parts, Radix Achyranthis Bidentatae 10 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Codonopsis 8 parts, Cortex Acanthopancis 10 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 5 parts, Flos Lonicerae 6 parts, Herba Lycopi 7 parts, Semen Coicis 8 parts, Radix Paeoniae Rubra 9 parts, Semen Lepidii (Semen Descurainiae) 4 parts, Medulla Tetrapanacis 12 parts and 6 parts, Radix Rubiae.
Preparation technology is with embodiment 1.
Embodiment 5
The each raw material of the present invention is taken: the Radix Astragali 20 parts, 16 parts, Poria, Fructus Lycii 17 parts by following weight portion, Stigma Maydis 13 parts, Radix Achyranthis Bidentatae 12 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Radix Codonopsis 10 parts, Cortex Acanthopancis 8 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 9 parts, Flos Lonicerae 4 parts, Herba Lycopi 5 parts, Semen Coicis 10 parts, Radix Paeoniae Rubra 7 parts, Semen Lepidii (Semen Descurainiae) 6 parts, Medulla Tetrapanacis 10 parts and 8 parts, Radix Rubiae.
Preparation technology is with embodiment 1.
The clinical observation of embodiment 6 medicine composite for curing nephropathy of the present invention
1, case-data: that selects hospital ward and outpatient clinic meets stagnation of dampness due to deficiency of the spleen type Primary Nephrosis patient 70 example, wherein, man 49 example, female 21 example; The oldest 60 years old, minimum 21 years old, 34 years old mean age; Be in hospital 7-46 days, average time in hospital 26 days.
2, diagnosis basis:
(1) Western medicine diagnose standard:
With reference to the diagnostic criteria about nephrotic syndrome in " about primary glomerulopathy typing and treatment and the diagnostic criteria symposium summary " of the peaceful meeting revision in Anhui in 1992.
1) High-grade Proteinuria (24h >=3.5g);
2) hypoproteinemia (serum albumin≤30g/L);
3) obvious edema;
4) hyperlipemia.
With two indispensabilities of going forward.Getting rid of Secondary cases nephrotic syndrome (systemic lupus erythematosus (sle), diabetes, anaphylactoid purpura, multiple myeloma etc.) just diagnosable is primary nephrotic syndrome.
(2) stagnation of dampness due to deficiency of the spleen disease CM syndrome differentiation criterion: puffiness of the face and dropsy of the feet, repeatedly growth and decline, increases the weight of after labor or in the afternoon.Gastral cavity is swollen anorexia, complexion is white all of a sudden, and god is tired weak, and oliguria color is clear, stool or half congealed.White and slippery fur, thready and weak pulse.
3, case standard is included in:
(1) age 18-60 year;
(2) Western medicine diagnose standard is met;
(3) traditional Chinese medical science stagnation of dampness due to deficiency of the spleen syndrome CM syndrome differentiation criterion is met;
(4) clinical observation " Informed Consent Form " is signed.
4, Excluded cases standard:
(1) clinical observation " Informed Consent Form " is not signed;
(2) edema that causes of other Non renal, as cardiac edema, liver source property edema, nutritional edema, incretion edema etc.;
(3) drug allergy or can not resistance to receptor is used to this research;
(4) cardiovascular and cerebrovascular vessel, liver, endocrine and hemopoietic system severe primary disease patient is merged, psychotic;
(5) renal edema of Secondary cases nephrotic syndrome, and other types, as renal failure, Renal vascular lesions etc.;
(6) dyslipidemia of other types, as hepatopathy, Nutrition and Metabolism obstacle etc.;
(7) eliminant physical property Liver and kidney factor, as antibiotic, antipyretic-antalgic class Western medicine etc.
5, case standard is rejected:
(1) rear discovery is included in exclusion standard disease patient;
(2) case of medication is not specified by testing program;
(3) drug administration process data logging is incomplete, cannot judge curative effect person.
6, to come off and termination criteria:
(1) observe in patient exit voluntarily, person lost to follow-up;
(2) there is the person that should not continue reception test such as complication or special physiological change in experimenter;
(3) serious adverse reaction occurs person in test, should stop clinical trial in time.
Come off and answer itemized record reason with the case stopped, and the switching of its last curative effect testing result is added up for final result.
7, usage and dosage:
Take medicine composite for curing of the present invention, capsule prepared by Example 1, every capsules containing crude drug amount 0.4g, every day 3 times, each 3, after meal half an hour warm water delivery service.Within 30 days, be a course for the treatment of, treat after terminating 3 courses for the treatment of and carry out therapeutic evaluation.
8, curative effect determinate standard:
With reference to the standard that 1992 " national primary glomerulopathy typing and clinical diagnosis symposium summary " is drafted.
(1) clinic control: the symptom and signs such as edema disappear completely; After treatment, continuous 3 24h urine protein quantitation continue to be less than 0.1g, and serum albumin returns to more than 35g.Blood T-CHOL, triglyceride are normal, normal renal function.
(2) effective: the symptoms such as edema and sign disappear substantially; after treatment, continuous 3 inspection 24h urine protein quantitation are between 0.1-0.5g; between serum albumin 30-35g; blood T-CHOL, triglyceride are close normal, normal renal function or normal (differ with normal value and be no more than 15%).
(3) effective: the symptoms such as edema and sign take a favorable turn; After treatment between continuous 3 24h urine protein quantitation 0.5-2g, blood T-CHOL, glycerol three are cruel than front making moderate progress, and renal function makes moderate progress.
(4) invalid: the symptom and signs such as edema are without being clearly better, and 24h urine protein quantitation > 2g, lab testing is all without improvement.
9, therapeutic effect:
In clinical observation process, come off 6 routine cases, and wherein 3 routine patients take a turn for the better backed off after random, and effectively to add up curative effect, the invalid backed off after random of 3 routine patient, with invalid statistics curative effect, all the other all complete clinical observation.Efficacy result is as follows: clinic control 16 example (22.9%), effective 34 examples (48.6%), effective 16 examples (22.9%), invalid 4 examples (5.71%), total effective rate 94.3%.In therapeutic process, vital sign steadily and without serious adverse reactions such as allergy, show that the clinical application of we is safely and effectively, is worth studying and applying further.
In addition, table 1 gives treatment Plasma Before And After albumin and compares, specific as follows:
Two groups, table 1. treatment Plasma Before And After albumin compares
| Group | Number of cases | Before treatment | After treatment |
| Treatment group | 70 | 20.95±3.24 | 34.22±2.35 ** |
Note: with ratio before treatment
*p < 0.05,
*p < 0.01.
Can find out, after treatment, plasma albumin comparatively treats front comparing difference remarkable statistical significance (P < 0.01), and drug regimen of the present invention is described, and I am with the obvious advantage in raising plasma albumin.
Claims (7)
1. treat a pharmaceutical composition for nephropathy, it is characterized in that, its raw material primarily of following weight portion obtains: Radix Astragali 18-20 part, Poria 16-18 part, Fructus Lycii 15-17 part, Stigma Maydis 13-15 part, Radix Achyranthis Bidentatae 10-12 part, Rhizoma Atractylodis Macrocephalae 12-15 part, Radix Codonopsis 8-10 part, Cortex Acanthopancis 8-10 part, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 5-9 part, Flos Lonicerae 4-6 part, Herba Lycopi 5-7 part, Semen Coicis 8-10 part, Radix Paeoniae Rubra 7-9 part, Semen Lepidii (Semen Descurainiae) 4-6 part.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, described pharmaceutical composition also comprises Medulla Tetrapanacis 10-12 part and Radix Rubiae 6-8 part.
3. pharmaceutical composition as claimed in claim 2, is characterized in that, its raw material primarily of following weight portion obtains: the Radix Astragali 19 parts, 17 parts, Poria, Fructus Lycii 16 parts, Stigma Maydis 14 parts, Radix Achyranthis Bidentatae 11 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, Radix Codonopsis 9 parts, Cortex Acanthopancis 9 parts, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 7 parts, Flos Lonicerae 5 parts, Herba Lycopi 6 parts, Semen Coicis 9 parts, Radix Paeoniae Rubra 8 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Medulla Tetrapanacis 11 parts, 7 parts, Radix Rubiae.
4. the pharmaceutical composition as described in as arbitrary in claim 1-3, it is characterized in that, described pharmaceutical composition is oral formulations.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, described oral formulations is tablet or capsule.
6. the purposes of the pharmaceutical composition as described in as arbitrary in claim 1-3 in preparation treatment Primary Nephrosis medicine.
7. the purposes of the pharmaceutical composition as described in as arbitrary in claim 1-3 in preparation treatment stagnation of dampness due to deficiency of the spleen type Primary Nephrosis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510067309.7A CN104623415A (en) | 2015-02-07 | 2015-02-07 | Pharmaceutical composition for treating nephropathy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510067309.7A CN104623415A (en) | 2015-02-07 | 2015-02-07 | Pharmaceutical composition for treating nephropathy and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104623415A true CN104623415A (en) | 2015-05-20 |
Family
ID=53202977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510067309.7A Pending CN104623415A (en) | 2015-02-07 | 2015-02-07 | Pharmaceutical composition for treating nephropathy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104623415A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331155A (en) * | 2018-12-24 | 2019-02-15 | 江苏省中医院 | For preventing and treating the Chinese medicine composition of simple cyst of kidney |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259232A (en) * | 2008-04-25 | 2008-09-10 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating nephrotic syndrome and preparation thereof |
-
2015
- 2015-02-07 CN CN201510067309.7A patent/CN104623415A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259232A (en) * | 2008-04-25 | 2008-09-10 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating nephrotic syndrome and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘建华 等: "芪莲茅根汤治疗蛋白尿型IgA肾病临床观察与实验研究", 《天津中医药》 * |
| 李琦 等: "行气消白汤治疗脾虚湿困型原发性肾病综合征30例", 《中国中医药信息杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331155A (en) * | 2018-12-24 | 2019-02-15 | 江苏省中医院 | For preventing and treating the Chinese medicine composition of simple cyst of kidney |
| CN109331155B (en) * | 2018-12-24 | 2021-06-18 | 江苏省中医院 | Traditional Chinese medicine composition for preventing and treating simple renal cyst |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101912585B (en) | Medicament for treating myoma of uterus and preparation method thereof | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN102526498A (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN103585479A (en) | Blood-replenishing pill and blood-replenishing capsule for treating iron-deficiency anemia | |
| CN102988733A (en) | Traditional Chinese medicine composition for treating postpartum hypogalactia and preparation method thereof | |
| CN103933513B (en) | Traditional Chinese medicine composition for removing acnes | |
| CN105031454A (en) | Medicine for treating pulmonary tuberculosis | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN102648969B (en) | Complex Chinese medicine preparation for reinforcing kidney | |
| CN105944020B (en) | Traditional Chinese medicine for treating ovarian function decline | |
| CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
| CN104436121B (en) | It is a kind of to treat irregular menstruation, small distention and fullness in the abdomen, the medicine to fail to be impregnated for a long time | |
| CN104623415A (en) | Pharmaceutical composition for treating nephropathy and application thereof | |
| CN106420970A (en) | Pharmaceutical composition for curing premature ovarian failure | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN105327171A (en) | Traditional Chinese medicine electuary for treating mastitis and preparing method thereof | |
| CN105213905A (en) | A kind of Chinese medicine composition and application thereof preventing and treating postmenopausal osteoporosis | |
| CN101375955B (en) | Sperm-passing formulation for treating non-ejaculation symptom and preparation method thereof | |
| CN104721313A (en) | Nursing medicine for treating acute waist injury | |
| CN103800561A (en) | Traditional Chinese medicine for treating renal hematuria | |
| CN103705856B (en) | For preventing the Chinese medicine composition of chemicotherapy acute radio-reaction | |
| CN107753800A (en) | A kind of Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN102671021B (en) | Chinese medicament for treating chronic catarrhal otitis media and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150520 |